Solid Tumor Clinical Trials in San Francisco, California

13 studies are recruiting for solid tumor in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

   The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to <18 years of age with soma…

   Stage

   Phase 1

   Ages

   2 to 18

   Site

   UCSF Benioff Children's Hospital, San Francisco, California

   Locations

   6 in total

   Run by

   ITM Solucin GmbH

   See if you can join NCT06441331 on ClinicalTrials.gov

2. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

   BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco (UCSF), San Francisco, California

   Locations

   49 in total

   Run by

   Institut de Recherches Internationales Servier

   See if you can join NCT05786924 on ClinicalTrials.gov

3. STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

   This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 [PD-1]) in advanced unresectable or metastatic tumors. The Phase 2…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   10 in total

   Run by

   STORM Therapeutics LTD

   See if you can join NCT06975293 on ClinicalTrials.gov

4. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

5. Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

   GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   11 in total

   Run by

   Georgiamune Inc

   See if you can join NCT06425926 on ClinicalTrials.gov

6. A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

   Fibroblast activation protein (FAP) is a cell surface protein that is highly expressed on the surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial cancers, whereas limited expression of FAP is observed in normal tissues. In some cancers of mesench…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Medical Center, San Francisco, California

   Locations

   41 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04939610 on ClinicalTrials.gov

7. Imaging of Solid Tumors Using 18F-TRX

   This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan. It specifically targets and detects labile (unstable) iron levels within tissues, including tumor…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   Rahul Aggarwal

   See if you can join NCT06942104 on ClinicalTrials.gov

8. A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

   This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]); and the dose expansion stage is to evaluate the preliminary antitumor act…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Exelixis Clinical Site #5, San Francisco, California

   Locations

   11 in total

   Run by

   Exelixis

   See if you can join NCT06952010 on ClinicalTrials.gov

9. PET [89Zr]DFO-starPEG in Solid Tumors

   This is a first-in-human, pilot study of the novel PET-imaging radiotracer [89Zr]DFO-starPEG. The study is designed to obtain preliminary data to support future development of this agent as an imaging surrogate to visualize enhanced permeability and retention (EPR)-mediated tracer uptake before adm…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   Robert Flavell, MD, PhD

   See if you can join NCT06894745 on ClinicalTrials.gov

10. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

    The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expa…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCSF, San Francisco, California

    Locations

    19 in total

    Run by

    NiKang Therapeutics, Inc.

    See if you can join NCT06586957 on ClinicalTrials.gov

11. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

    This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tum…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California at San Francisco, San Francisco, California

    Locations

    15 in total

    Run by

    Tango Therapeutics, Inc.

    See if you can join NCT06810544 on ClinicalTrials.gov

12. A Beta-only IL-2 ImmunoTherapY Study

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

    Locations

    27 in total

    Run by

    Medicenna Therapeutics, Inc.

    See if you can join NCT05086692 on ClinicalTrials.gov

13. First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

    The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and have exhausted other therapeutic options.CRB-601 targets a protein called avb8 integrin which is expre…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California San Francisco, San Francisco, California

    Locations

    26 in total

    Run by

    Corbus Pharmaceuticals Inc.

    See if you can join NCT06603844 on ClinicalTrials.gov